Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod

Trial Profile

Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 16 Apr 2015 Planned number of patients changed from 200 to 40, according to to ClinicalTrials.gov record.
    • 16 Apr 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
    • 11 Sep 2014 Planned End Date changed from 30 May 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top